JP2009534457A - がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 - Google Patents

がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 Download PDF

Info

Publication number
JP2009534457A
JP2009534457A JP2009507165A JP2009507165A JP2009534457A JP 2009534457 A JP2009534457 A JP 2009534457A JP 2009507165 A JP2009507165 A JP 2009507165A JP 2009507165 A JP2009507165 A JP 2009507165A JP 2009534457 A JP2009534457 A JP 2009534457A
Authority
JP
Japan
Prior art keywords
independently
alkyl
aryl
compound according
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534457A5 (https=
Inventor
ニキュルスキュ−デュヴァズ，ダン
スプリンガー，キャロライン，ジョイ
マライス，リチャード，マルコム
ディクストラ，ハルメン
メナード，デルフィーン
ニキュルスキュ−デュヴァズ，イオン
デービス，ローレンス
ノーリー，アルノー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0608268.9A external-priority patent/GB0608268D0/en
Application filed by Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2009534457A publication Critical patent/JP2009534457A/ja
Publication of JP2009534457A5 publication Critical patent/JP2009534457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009507165A 2006-04-26 2007-04-26 がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 Pending JP2009534457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74563306P 2006-04-26 2006-04-26
GBGB0608268.9A GB0608268D0 (en) 2006-04-26 2006-04-26 Therapeutic compounds
PCT/GB2007/001534 WO2007125330A1 (en) 2006-04-26 2007-04-26 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2009534457A true JP2009534457A (ja) 2009-09-24
JP2009534457A5 JP2009534457A5 (https=) 2010-06-03

Family

ID=38421488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507165A Pending JP2009534457A (ja) 2006-04-26 2007-04-26 がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体

Country Status (7)

Country Link
US (1) US7951819B2 (https=)
EP (1) EP2013207B1 (https=)
JP (1) JP2009534457A (https=)
AU (1) AU2007245495A1 (https=)
CA (1) CA2649994A1 (https=)
NO (1) NO20084688L (https=)
WO (1) WO2007125330A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518089A (ja) * 2010-02-01 2013-05-20 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2024526198A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers
AU2008337286B2 (en) * 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
CA2797237C (en) 2010-04-21 2018-05-22 The Regents Of The University Of Michigan Fluoroscopy-independent, endovascular aortic occlusion system
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US9474882B2 (en) 2013-02-26 2016-10-25 Prytime Medical Devices, Inc. Fluoroscopy-independent balloon guided occlusion catheter and methods
CA2923419A1 (en) 2013-09-09 2015-03-12 Pryor Medical Devices, Inc. Low-profile occlusion catheter
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
AU2015274743B2 (en) 2014-06-10 2016-11-10 Prytime Medical Devices, Inc. Conduit guiding tip
JP6472536B2 (ja) 2015-03-19 2019-02-20 プリタイム・メディカル・デバイシーズ・インコーポレイテッドＰｒｙｔｉｍｅ Ｍｅｄｉｃａｌ Ｄｅｖｉｃｅｓ，Ｉｎｃ． 低プロファイル閉塞バルーンカテーテル用のシステムおよび方法
EP3463106B1 (en) 2016-06-02 2023-10-25 Prytime Medical Devices, Inc. System for low profile occlusion balloon catheter
AU2017312970B2 (en) * 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
EP3568190B1 (en) 2017-01-12 2023-11-22 The Regents of the University of California Endovascular perfusion augmentation for critical care
PL3601233T3 (pl) 2017-03-27 2025-01-07 HYDRO-QUéBEC Sole do zastosowania w kompozycjach elektrolitowych lub jako dodatki do elektrod
CN110769749B (zh) 2017-04-21 2023-05-09 加利福尼亚大学董事会 用于部分主动脉闭塞的主动脉流量计和泵
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US12011172B2 (en) 2018-08-06 2024-06-18 Prytime Medical Devices, Inc. Occlusion catheter system for full or partial occlusion
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
PH12022550298A1 (en) 2019-08-08 2023-04-24 B C I Pharma Quinoline derivatives as protein kinase inhibitors
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
JP7835406B2 (ja) 2020-03-16 2026-03-25 サータス クリティカル ケア， インコーポレイテッド 血流制御デバイス、システム、及び方法、並びにそれらのエラー検出
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
US12102330B2 (en) 2021-03-18 2024-10-01 Prytime Medical Devices, Inc. Vascular occlusion catheter for partial occlusion or full occlusion
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
EP4622971A1 (en) 2022-11-24 2025-10-01 B.C.I. Pharma Pyridine derivatives as protein kinase inhibitors
WO2025021943A1 (en) 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US20040082583A1 (en) * 2000-11-29 2004-04-29 Mui Cheung Chemical compounds
WO2006024834A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665863A (en) 1979-10-31 1981-06-03 Tokyo Organ Chem Ind Ltd Novel aniline derivative, its preparation and pesticide containing the same
JPS5738777A (en) 1980-08-19 1982-03-03 Sogo Yatsukou Kk 2-sufanilamidopyrathyn derivative
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
DE69534180T2 (de) 1994-09-22 2006-03-02 Licentia Ltd. Promotor der tie rezeptor protein kinase
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
NZ503432A (en) 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB2356398A (en) 1999-11-18 2001-05-23 Lilly Dev Ct S A Preparation of arylsulfamides
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
NZ532780A (en) 2001-12-21 2006-10-27 Wellcome Trust Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them
US20060128783A1 (en) 2002-08-09 2006-06-15 Dinsmore Christopher J Tyrosine kinase inhibitors
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US20040082583A1 (en) * 2000-11-29 2004-04-29 Mui Cheung Chemical compounds
WO2006024834A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518089A (ja) * 2010-02-01 2013-05-20 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2015180675A (ja) * 2010-02-01 2015-10-15 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2024526198A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物
JP2024526197A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物

Also Published As

Publication number Publication date
WO2007125330A1 (en) 2007-11-08
CA2649994A1 (en) 2007-11-08
US20090325945A1 (en) 2009-12-31
US7951819B2 (en) 2011-05-31
EP2013207A1 (en) 2009-01-14
NO20084688L (no) 2009-01-26
AU2007245495A1 (en) 2007-11-08
EP2013207B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
JP2009534457A (ja) がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体
JP4926973B2 (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
JP5511680B2 (ja) ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
JP2008525409A (ja) 治療用化合物としてのピラジンおよびピリジンならびにその誘導体
JP2011518819A (ja) アリール−キノリル化合物及びその使用
ES2385103T3 (es) Compuestos de imidazo[4,5-b]piridin-2-ona y análogos de los mismos como compuestos terapéuticos contra el cáncer
HK1100368B (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
HK1148521B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507